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A vast amount of “omic” data has been accumulated for
most cancer types that are potentially relevant to the
development of protein-based cancer biomarkers. Most
such data are derived from transcriptomic or proteomic
analysis of tumor tissue, tumor cell lines, or biological
fluids either proximal to tumors such as effusions or distal,
notably serum, and plasma. Protein biomarker candidates
embedded in these data may be relevant to the diagnosis of
cancer through blood-based testing or may have utility to
classify tumors, predict response to therapy, or help monitor
disease progression, regression, and recurrence. The ques-
tion is how do we fast-track biomarker development given
the availability of so much pertinent data?
While there are no simple answers, two important
resources would help fast-track the process substantially.
One is the availability of specimen resources and the other
is the availability of affinity capture agents. These resources
are particularly needed for proteomic studies aimed at
developing blood-based cancer biomarkers but are also
needed for biomarker development across the board. High-
quality standardized reference specimens meticulously
procured and processed under exacting conditions to
preserve their contents, and therefore their value, are
needed to rigorously test or triage candidate markers.
Affinity capture agents, notably antibodies, are also needed
to allow investigations of candidate markers in ways that
are not readily feasible with the current standard tool for
proteomics, namely mass spectrometry. Antibodies allow
elucidation of tissue distribution and subcellular localiza-
tion of the proteins they targeted and assessment of their
occurrence as part of complexes and allow development of
high throughput assays for their measurement using various
assay formats. The availability of these two important
resources for biomarker development would allow testing
of candidate biomarkers using standardized tissue specimen
and standardized reagents. As a result, meaningful perfor-
mance comparisons can be made between biomarker
candidates derived from heterogeneous studies to aid in
developing marker panels, comparing performance of
biomarkers between disease groups and their performance
for specific applications from early diagnosis to disease
classification and monitoring.
The next question is how to facilitate the development of
these two important resources for fast-tracking biomarkers?
An organized effort is necessary for this purpose that may
benefit from designating funds specifically to this effect,
both for specimen and antibody procurement and for
distribution to biomarker developers. Funding sources for
cancer research consist primarily of the National Institutes
of Health, notably the National Cancer Institute, Industry
and a multitude of philanthropic organizations and individ-
ual contributors committed to the fight against cancer in
general or specific organ types of cancer in particular. A
cooperative effort among the stakeholders to provide
funding for these two resources would be highly beneficial.
A case in point is the Biomarkers Consortium (http://www.
biomarkersconsortium.org) which is a public–private part-
nership managed by the Foundation for the National
Institutes of Health that aims to facilitate biomarker
development. Important objectives of the Consortium
include facilitating drug development through the applica-
tion of biomarkers and helping achieve personalized
medicine through predictive markers. While the Consor-
tium goals do not particularly emphasize the development
of specimen resources and affinity capture agents, the
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formation of this public–private consortium supports the
view that stakeholders can work together to fast-track
biomarker development, and therefore, initiatives to devel-
op these two important resources would garner substantial
support.
While organizations, notably the National Cancer Insti-
tute, have recognized the need for specimen resources and
affinity capture agents, plans for developing these two
resources remain sketchy. Given the relevance of these
resources to biomarker development, and more broadly to
translational research, concrete steps to be taken for
specimen collection could include the following:
1. Clinical trials should be expected to include specimen
collections for the purpose of biomarker development
and/or testing, with adequate support allocated to
specimen collection.
2. Programs with a significant clinical/translational re-
search component should be expected to develop
specimen resources as part of their activities through a
set aside or other equally effective mechanism, specif-
ically for funding these activities as opposed to vague
expectations that these needs would be met. A good
example is the NCI Early Detection Research Network
which has developed a process and allocated funds for
building and sharing a specimen resource for early
detection applications of biomarkers and for developing
a related informatics infrastructure (http://www.edrn.
nci.nih.gov).
3. A mechanism to deposit/share specimen resources with
a credit system to this effect should be developed.
While these ideas may not be novel and there are
certainly scenarios in which they are currently being
applied as illustrated, the emphasis here is on availability
of specimens specifically for biomarker development that
are collected under standardized operating procedures with
the intent to distribute specimens to qualified investigators
and projects.
The development of affinity capture agents for broad
applications including biomarker research has certainly
been considered and has been found to be quite challeng-
ing. The scope of such an effort may be difficult to define.
Potential technologies are quite varied with throughput,
cost and reach-through representing important issues. Yet,
some creative solutions are beginning to emerge. The effort
could be divided along tumor types or pathways for which
biomarkers are sought. Stakeholders would then take on the
task of assembling promising candidates for which affinity
capture agents are needed from available data. Until an
effective or a dominant alternative strategy for making
capture agents emerges, polyclonal and monoclonal anti-
bodies directed at several epitopes per candidate biomarker
would be the preferred choice. A case in point is the
development of antibodies directed at pancreatic cancer
candidate markers through support from the Lustgarten
foundations (http://www.lustgarten.org). If the numerous
foundations committed to the fight against cancer adopt the
development of antibodies against candidate biomarkers for
the cancer type they are committed to fight, the problem of
availability of antibodies against candidate cancer markers
would be effectively addressed. The vast collection of
resulting antibodies would be of substantial benefit for all
aspects of research.
There remains numerous issues pertaining to execution,
which would also need to be addressed. Not to be
overlooked are the responsibilities of investigators that
request to use such resources. In return for access to these
resources, there has to be a commitment to share data and
findings regarding marker candidate and antibody perfor-
mance. It is through such organized efforts that cancer
biomarker development and in particular, the promise of
proteomics, can be fulfilled.
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